adult
onset
hemophagocyt
lymphohistiocytosi
hlh
rare
condit
usual
secondari
either
precipit
infect
hematolog
malign
present
case
epsteinbarr
viru
associ
hlh
femal
receiv
treatment
glioblastoma
gbm
possibl
hlh
recogn
patient
gbm
often
featur
nonspecif
system
inflammatori
respons
syndrom
multiorgan
failur
cognit
declin
high
index
suspicion
increas
awar
help
improv
timeli
diagnosi
therapeut
epsteinbarr
viru
associ
hlh
patient
solid
organ
malign
pose
signific
challeng
individu
multidisciplinari
approach
essenti
manag
adultonset
hlh
provid
need
mind
high
mortal
rate
despit
treatment
hemophagocyt
lymphohistiocytosi
hlh
rare
disord
high
mortal
rate
pathophysiolog
hallmark
overact
ineffect
immun
system
hlh
initi
describ
best
recogn
pediatr
popul
howev
increas
recognit
disord
among
adult
hlh
categor
either
primari
famili
commonli
adult
secondari
underli
infect
autoimmun
metabol
malign
process
secondari
set
prompt
recognit
essenti
mortal
estim
median
overal
surviv
among
patient
underli
malign
month
systemat
review
secondari
caus
patient
hlh
underli
hematolog
malign
found
n
n
underli
solid
organ
malign
describ
case
hlh
patient
undergo
activ
treatment
glioblastoma
gbm
evid
increas
frequenc
opportunist
infect
set
persist
treatmentrel
lymphopenia
best
knowledg
first
case
report
describ
diagnosi
hlh
patient
gbm
subsequ
manag
case
note
singl
institut
case
seri
hlh
clinic
detail
avail
increas
awar
diagnost
criterion
improv
identif
report
ultim
allow
improv
individu
decis
make
patient
level
patient
otherwis
healthi
femal
initi
present
rightsid
weak
express
aphasia
outsid
hospit
imag
find
reveal
left
parietalthalam
lesion
suspici
highgrad
glioma
underw
subtot
resect
patholog
reveal
gbm
molecular
marker
suggest
aggress
phenotyp
ie
unmethyl
mgmt
promotor
without
isocitr
dehydrogenas
mutat
time
diagnosi
karnofski
perform
statu
entir
attribut
malign
slightli
underweight
bmi
kgm
subsequ
start
chemoradi
cours
complic
obstruct
hydrocephalu
requir
implant
intraventricular
periton
shunt
despit
standard
therapi
gbm
continu
progress
start
bevacizumab
metronom
daili
low
dose
temozolomid
secondlin
treatment
approxim
week
prior
recent
hospit
evalu
hypoxem
respiratori
failur
initi
infecti
workup
includ
blood
respiratori
cultur
well
respiratori
viral
panel
neg
improv
empir
antibiot
thought
pneumocysti
jiroveci
pneumonia
pjp
given
improv
initi
steroid
trimethoprim
sulfamethoxazol
tmpsmx
start
tmpsmx
absolut
neutrophil
count
began
drop
subsequ
readmit
malais
cough
found
absolut
neutrophil
count
l
notabl
absolut
lymphocyt
count
remain
persist
low
sinc
initi
chemoradi
readmit
week
prior
recent
hospit
increas
short
breath
admiss
test
posit
coronaviru
tmpsmx
chang
dapson
order
continu
prophylact
pjp
coverag
seen
outpati
oncolog
offic
visit
week
prior
admiss
time
respiratori
statu
return
baselin
karnofski
perform
statu
absolut
neutrophil
count
began
recov
howev
absolut
lymphocyt
count
remain
l
readmit
worsen
short
breath
confus
found
hypotens
tachycard
hypoxem
laboratori
studi
reveal
worsen
pancytopenia
elev
liver
enzym
abdomin
ultrasound
mri
demonstr
heterogen
liver
coars
echotextur
splenomegali
figur
signific
anteced
alcohol
use
liver
diseas
mri
brain
reveal
stabl
appear
gbm
start
fluid
antibiot
liver
injuri
initi
thought
drug
induc
set
bevacizumab
tmpsmx
temozolomid
dapson
routin
type
screen
note
new
warm
autoantibodi
posit
directantiglobulin
test
concern
hemolyt
anemia
although
total
indirect
direct
bilirubin
markedli
elev
could
altern
explain
liver
injuri
mgdl
respect
fibrinogen
level
also
note
low
elev
ddimer
ngml
mild
coagulopathi
pt
aptt
consist
liver
injuri
viral
studi
reveal
epsteinbarr
viru
ebv
quantit
load
intern
unit
per
ml
iuml
known
histori
ebv
stare
methylprednisolon
intraven
immunoglobulin
littl
effect
requir
multipl
transfus
blood
platelet
cryoprecipit
dissemin
intravascular
coagul
rituximab
initi
follow
daili
anakinra
notabl
respons
hematolog
paramet
requir
less
transfus
figur
unfortun
patient
condit
continu
deterior
becam
oligur
echocardiogram
reveal
takotsubopattern
cardiomyopathi
went
develop
pancreat
due
hypertriglyceridemia
given
extens
multiorgan
failur
famili
wish
initi
ventil
support
dialysi
patient
pass
away
shortli
deescal
care
patient
secondari
hlh
divers
present
make
diagnosi
difficult
obtain
frequent
use
diagnost
criterion
develop
pediatr
popul
aid
enrol
clinic
trial
commonli
use
adult
popul
usual
greater
equal
five
eight
diagnost
criteria
support
diagnosi
adult
tabl
retrospect
evalu
diagnost
perform
criteria
across
pediatr
adult
popul
debaugni
et
al
demonstr
sensit
specif
adult
five
diagnost
criteria
initi
present
notabl
author
exclud
criteria
reduc
nk
cytotox
elev
solubl
analysi
role
evalu
nkcell
activ
best
describ
pediatr
popul
usual
done
adult
patient
level
uml
cohort
patient
preval
hlh
yield
posit
predict
valu
sensit
specif
although
hemophagocytosi
hallmark
patholog
featur
hlh
patient
undergo
bone
marrow
biopsi
due
critic
ill
hemophagocytosi
neither
sensit
specif
gupta
et
al
previous
demonstr
pediatr
patient
median
time
diagnosi
hlh
initi
bone
marrow
aspir
day
suggest
diagnosi
often
made
prior
outcom
bone
marrow
biopsi
given
high
index
suspicion
hlh
patient
bone
marrow
aspir
evid
hemophagocytosi
would
alter
initi
treatment
approach
notabl
patient
receiv
standard
therapi
gbm
temozolomid
oral
alkyl
agent
commonli
associ
lymphopenia
increas
risk
opportunist
infect
due
concern
diseas
progress
patient
also
receiv
signific
dose
corticosteroid
bevacizumab
monoclon
antibodi
reduc
angiogenesi
inhibit
vegf
commonli
use
manag
gbm
also
associ
immunosuppress
infect
complic
hiv
test
neg
howev
sever
lymphopenia
count
microbiolog
evid
ebv
infect
addit
recent
treat
pjp
suspect
like
trigger
hlh
patient
reactiv
ebv
set
immunosuppress
conjunct
temozolomid
therapi
set
gbm
ebv
commonli
associ
infect
trigger
result
diagnosi
hlh
associ
poor
outcom
great
geograph
variabl
diagnosi
ebvassoci
hlh
greatest
experi
driven
asia
etoposid
dexamethason
form
mainstay
initi
treatment
includ
patient
ebvassoci
hlh
confirm
longterm
analysi
studi
administr
etoposid
patient
difficult
due
sever
hepat
dysfunct
thu
chose
initi
therapi
corticosteroid
intraven
immunoglobulin
intent
start
etoposid
within
window
rituximab
monoclon
antibodi
shown
effect
reduc
symptom
inflamm
ebv
viral
load
patient
ebvassoci
hlh
patient
continu
deterior
therapeut
decis
start
therapi
anakinra
versu
target
monoclon
antibodi
alemtuzumab
agent
use
refractori
set
manag
hlh
case
pose
sever
diagnost
therapeut
challeng
despit
make
diagnosi
toxic
profil
propos
intervent
consider
addit
patient
compet
risk
mortal
underli
malign
sever
infect
complic
multiorgan
failur
increas
use
immunosuppress
cytotox
regimen
manag
advanc
malign
like
increas
recognit
hlh
patient
solid
organ
malign
increas
awar
research
best
therapeut
approach
reduc
high
mortal
rate
addit
patient
highgrad
glioma
treat
temozolomid
monitor
sign
hlh
hlh
rare
highli
morbid
condit
adult
present
first
case
patient
develop
ebvassoci
hlh
follow
therapi
underli
gbm
addit
high
index
suspicion
diagnosi
especi
patient
solid
organ
malign
care
consid
approach
need
extrapol
therapeut
approach
evid
base
larg
deriv
pediatr
popul
financi
compet
interest
disclosur
vk
receiv
support
nih
train
grant
content
sole
respons
author
necessarili
repres
offici
view
nih
author
relev
affili
financialinvolv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
write
assist
util
product
manuscript
author
state
follow
principl
outlin
declar
helsinki
human
anim
experiment
investig
author
state
obtain
verbal
written
inform
consent
patient
next
kin
inclus
medic
treatment
histori
within
case
report
open
access
